Georgetown University

Duke University

George Mason University

George Mason Research Foundation, Inc.

University of Pennsylvania

University of Virginia Patent Foundation

Mikell Paige

Milton L Brown

Kenneth J Kellar

Yingxian Xiao

Edward D Levin

Amir H Rezvani

Yong Liu

Yun Michael Shim

Lance A Liotta

Venkata Mahidhar Yenugonda

Virginia Espina

Alessandra Luchini

Aykut Uren

Alessandra Luchini Kunkel

Partha Banerjee

Amanda Haymond Still

Maria Laura Avantaggiati

Thomas H Walls

Simeng Suy

Mohamad Gabriel Alameh

Manuel Carrasco

Suman Alishetty

Michael Daro Buschmann

Gregory Petruncio

Todd Hansen

Scott Grindrod

Gullay Bulut

George Kosturko

Jeffrey A Torestsky

Shankar Jagadeesh

Kathryn D Sheikh

Young-Ok You

Disclosed herein are methods of increasing the potency of nucleic acid loaded lipid nanoparticles (naLNPs) through certain novel and surprisingly superior LNP manufacturing techniques. Also disclosed are pharmaceutical compositions containing naLNPs manufactured according to the manufacturing methods described herein. The methods disclosed herein overcome major technical difficulties and high costs associated with previous LNP manufacturing techniques. The methods disclosed herein, therefore, greatly improve the industrial production of LNPs in unexpected ways thereby providing more potent naLNPs for nucleic acid delivery. Specifically, the invention disclosed herein are methods that show increased potency naLNPs due to increased mixing concentration of the lipids and mRNA during assembly.

Methods of lipid nanoparticle manufacture and compositions derived therefrom

The present disclosure relates to compounds, complexes, compositions, kits and methods for determining interacting and/or binding sites between e.g., proteins, proteins and nucleic acids, proteins and small molecules, or intrachain protein domains. The disclosure provides rapid and direct positive identification of the contact interface region between such molecules, and can be applied to individual interacting pairs, as well as large-scale or global interactions.

Binding domain mapping and compounds, compositions, complexes, methods, and kits related thereto

Methods of treating or preventing cancer, diabetes, and/or obesity in a subject are provided. The methods comprise administering to a subject a therapeutically effective amount of an SLC25A1 inhibitor as described herein. Also provided herein are pharmaceutical compositions comprising an SLC25A1 inhibitor and a chemotherapeutic agent. Further provided herein are methods of inhibiting SLC25A1 in a cell.

Small molecule inhibitors of SLC25A1

Tacrolimus is an immunosuppressant drug. The present disclosure provides an anti-fibrotic agent by transforming Tacrolimus, such that the anti-fibrotic agent is used for treating fibrosis. The anti-fibrotic agent is not immunosuppressant. In one embodiment, the present invention provides a method to transform Tacrolimus into an anti-fibrotic agent.

Anti-fibrotic agent

In one aspect, the invention relates to compositions comprising peptides and/or peptidomimetic compounds, methods of making same, pharmaceutical compositions comprising same, and methods of treating various diseases, including, but not limited to, arthritis, obstructive lung disease, psoriasis, asthma, a defect in hematopoiesis, a neoplasia, a fungal infection, a parasitic infection, or an autoimmune disease, such as, but not limited to, rheumatoid arthritis, atopic allergy, anaphylaxis, psoriasis, asthma, lupus erythematosis, a myeloid cell disorder, or a eosinophil cell disorder. In an aspect, the disclosed peptides and/or compounds inhibit the interaction of IL-1RAcP with the ST2 and IL33 receptor/cytokine complexes. In a further aspect, the disclosed peptides and/or compounds inhibit the interaction of IL-1RAcP with the IL-1R1 and IL-1&#x3b2; receptor/cytokine complexes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta

The present compositions and methods generally relate to the treatment of diseases, such as idiopathic pulmonary fibrosis (IPF) and neurodegenerative diseases related to tau aggregation. In particular, the compositions relate to compounds or pharmaceutically acceptable salts of Formula I: 

Macrocyclic lactones

The invention provides methods for the treatment of cancer in a subject comprising administering a dansyl-carbazole compound.

Fluorescent regulators of RASSF1A expression and human cancer cell proliferation

Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia.

2-halo-5-alkynyl-pyridyl nicotinic ligands

2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof

Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.

Phenyl-substituted nicotinic ligands, and methods of use thereof

The present application discloses compositions and methods useful for treating and preventing inflammation associated with inflammatory diseases and disorders.

Compositions and methods for treating inflammatory diseases

The invention encompasses compound and pharmaceutical composition comprising the compound of the following Formula (I): or pharmaceutically acceptable salts or prodrugs thereof, that are useful for inhibiting ezrin protein in a cell or for inhibiting the growth of a cancer cell.

Ezrin inhibitors and methods of making and using

Growing community of inventors

Fairfax Station, VA, United States of America

Mikell Paige